<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975285</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032547</org_study_id>
    <nct_id>NCT01975285</nct_id>
  </id_info>
  <brief_title>Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot &amp; Ankle Surgery</brief_title>
  <official_title>Prospective Randomized Double Blind Study to Evaluate the Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot &amp; Ankle Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study to evaluate the effects of dexamethasone as an addition
      to peripheral nerve block (Put the nerve to sleep with Bupivacaine a numbing medication) on
      length of pain relief (analgesia), postoperative narcotic (opioids) requirements, pain
      scores, and patient satisfaction after foot and ankle procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postoperative pain using a Verbal Rating Scale</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Postoperative will be measured at:
PACU every 30 minutes Home:12, 24, 48, and 72 hours. Also at 1 week, one and six months after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting will be measured with follow up</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Postoperative nausea and vomiting using a Verbal Rating Scale (0-10) at PACU, one week after surgery and one month after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>patient satisfaction using a Verbal Rating Scale (0-10)with the overall technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Opioid consumption obtained from the recorded data Perioperative use of opioid consumption inside hospital (recorded by study staff and data obtained from patient charts) Post discharge use of opioid consumption (data obtained from the follow up questionnaires approximately one week, one month and 6 months after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of analgesia</measure>
    <time_frame>one week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time in days and/or hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Foot and Ankle Procedures</condition>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% Bupivacaine with 1:200,000epinephrine + Dexamethasone 4mg(1 ml) per 20cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc</description>
    <arm_group_label>Saline group</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  100 patients (50 per group) undergoing foot and ankle procedures

          -  Willingness and ability to sign an informed consent document

          -  No allergies to anesthetic or analgesic medications

          -  American Society of Anesthesiologists (ASA)physical status Class I - III

          -  Aged 18-90 years,either sex

        Exclusion Criteria:

          -  Refusal to participate in the study

          -  Age&lt;18 or&gt; 90 years   -

          -  Contraindications to regional blockage including but not limited to:

          -  Patient refusal to regional blockade

          -  Infection at the site of needle insertion

          -  Systemic infection

          -  Bleeding diathesis or coagulopathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roya Yumul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roya Yumul, MD, PhD</last_name>
    <phone>310-423-5841</phone>
    <email>Roya.Yumul@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ofelia L Elvir Lazo, MD</last_name>
    <phone>310-423-5841</phone>
    <email>loanidoc@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kapil Anand, MD</last_name>
      <phone>310-423-5841</phone>
      <email>Kapil.Anand@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Ofelia L Elvir Lazo, MD</last_name>
      <phone>310-423-5841</phone>
      <email>loanidoc@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Hausman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Hernandez Conte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Thordarson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glenn Pfeffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Eng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alyse Mousette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofelia L Elvir Lazo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kapil Anand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Roya Yumul, M.D.,PhD.</investigator_full_name>
    <investigator_title>Residency program director, Department of anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Pain management</keyword>
  <keyword>Postoperative opioid requirements</keyword>
  <keyword>Perioperative outcomes</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Anesthetic adjuvant</keyword>
  <keyword>Analgesic adjuvant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Adjuvants, Anesthesia</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
